You are here

Open

Reset

NOTE: The Solicitations and topics listed on this site are copies from the various SBIR agency solicitations and are not necessarily the latest and most up-to-date. For this reason, you should visit the respective agency SBIR sites to read the official version of the solicitations and download the appropriate forms and rules.


If no search results for your keyword(s) were found, you are encouraged to review Agency omnibus solicitations for additional funding opportunities. Omnibus solicitations are structured to be broad, extensive Programmatic issuances with research areas related to the petitioning Agency and are not limited to predetermined Topics/Subtopics. If upon reviewing you have additional questions, you may consider reaching out to the respective Agency for clarification regarding acceptable proposals (https://www.sbir.gov/agency-contacts).

  1. PA-19-043: Novel Approaches for Relating Genetic Variation to Function and Disease (R43/R44 Clinical Trial Not Allowed)

    Release Date: 10-31-2018Open Date: 12-05-2018 Due Dates: Multiple Close Date: 09-05-2021

    Section I. Funding Opportunity Description Background Sequencing studies, including the 1000 Genomes Project and many disease studies, have identified more than 100 million sites in the human genome that vary among people. However, it is likely that most of the variants do not contribute to differences in function, traits, disease risk, or clinical outcomes. Thus, methods to determine which ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  2. PA-19-033 : Commercializing Understudied Proteins from the Illuminating the Druggable Genome Project (IDG) (R41/R42 Clinical Trial Not Allowed)

    Release Date: 10-24-2018Open Date: 12-05-2018 Due Dates: Multiple Close Date: 09-05-2021

    Background The human genome has revealed a great deal about the human proteome, though significant portions remain understudied. Only a subset of expressed proteins demonstrates the requisite properties to serve as targets for the development of therapeutics. Many bona fide drug targets likely remain to be discovered in the "Druggable Genome" (DG), which can be defined as a subset of the ~20,000 ...

    STTRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  3. PA-19-034 : Commercializing Understudied Proteins from the Illuminating the Druggable Genome Project (IDG) (R43/R44 Clinical Trial Not Allowed)

    Release Date: 10-24-2018Open Date: 12-05-2018 Due Dates: Multiple Close Date: 09-05-2021

    Background The human genome has revealed a great deal about the human proteome, though significant portions remain understudied. Only a subset of expressed proteins demonstrates the requisite properties to serve as targets for the development of therapeutics. Many bona fide drug targets likely remain to be discovered in the "Druggable Genome" (DG), which can be defined as a subset of the ~20,000 ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  4. PAS-19-317 : Advancing Research on Alzheimer's Disease (AD) and Alzheimer's-Disease-Related Dementias (ADRD) (R41/R42 Clinical Trial Optional)

    Release Date: 07-18-2019Open Date: 12-05-2019 Due Dates: Multiple Close Date: 09-05-2022

    Recent recommendations and milestones for AD/ADRD research from the National Alzheimer’s Project Act, the 2015 Alzheimer’s Disease Research Summit, the 2018 Alzheimer’s Disease Research Summit, and the 2019 Alzheimer’s Disease and Related Dementias Research Summit present a wide range of research and development proposals which, if pursued, can reduce the human burden and healthcare costs ...

    STTRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  5. RFA-NS-20-008 : HEAL Initiative: Development of Therapies and Technologies Directed at Enhanced Pain Management (R41/R42 Clinical Trial Required)

    Release Date: 10-04-2019Open Date: 12-08-2019 Due Dates: Multiple Close Date: 09-08-2022

    Purpose The purpose of this Funding Opportunity Announcement (FOA) aims to speed scientific solutions to stem the national opioid public health crisis by supporting the development of therapies and technologies directed at enhanced pain management through the Small Business Technology Transfer (STTR) program. Specifically, this FOA is focused on applications directed at improving pain measurement ...

    STTRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  6. RFA-NS-20-009 : RFA-NS-20-009

    Release Date: 10-03-2019Open Date: 12-08-2019 Due Dates: Multiple Close Date: 09-08-2022

    Purpose The purpose of this Funding Opportunity Announcement (FOA) aims to speed scientific solutions to stem the national opioid public health crisis by supporting the development of therapies and technologies directed at enhanced pain management through the Small Business Technology Transfer (STTR) program. Specifically, this FOA is focused on applications directed at improving pain measurement ...

    STTRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  7. RFA-NS-20-010 : HEAL INITIATIVE: Development of Therapies and Technologies Directed at Enhanced Pain Management (R43/R44- Clinical Trial Required)

    Release Date: 10-04-2019Open Date: 12-08-2019 Due Dates: Multiple Close Date: 09-08-2022

    Purpose The purpose of this Funding Opportunity Announcement (FOA) aims to speed scientific solutions to stem the national opioid public health crisis by supporting the development of therapies and technologies directed at enhanced pain management through the Small Business Innovation Research (SBIR) program. Specifically, this FOA is focused on applications directed at improving pain measurement ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  8. RFA-NS-20-011 : RFA-NS-20-011

    Release Date: 10-01-2019Open Date: 12-08-2019 Due Dates: Multiple Close Date: 09-08-2022

    Purpose The purpose of this Funding Opportunity Announcement (FOA) aims to speed scientific solutions to stem the national opioid public health crisis by supporting the development of therapies and technologies directed at enhanced pain management through the Small Business Innovation Research (SBIR) program. Specifically, this FOA is focused on applications directed at improving pain measurement ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  9. RFA-HG-20-016 : Novel Synthetic Nucleic Acid Technology Development (R43/R44) (Clinical Trial Not Allowed)

    Release Date: 03-19-2020Open Date: 03-25-2020 Due Dates: Multiple Close Date: 06-24-2022

    Purpose This Funding Opportunity Announcement (FOA) solicits R43/R44 grant applications to develop novel technologies that will enable no less than one order of magnitude improvement in commercial synthetic nucleic acid synthesis and constructs. Advances in genomics and more broadly in biomedical research have been greatly facilitated by significant and sustained synthetic nucleic acid increased ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  10. PAR-20-244 : Interactive Digital Media STEM Resources for Pre-College and Informal Science Education Audiences (SBIR) (R43/R44 Clinical Trial Not Allowed)

    Release Date: 06-25-2020Open Date: 08-04-2020 Due Dates: Multiple Close Date: 09-03-2022

    The educational objective of this FOA is to provide opportunities for eligible SBCs to submit NIH SBIR grant applications to develop IDM STEM products that address student career choice and health and medicine topics for: (1) pre-kindergarten to grade 12 (P-12) students and teachers or (2) informal science education (ISE) audiences. The second educational objective is to inform the American public ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government